Authors : Chetna; Ashutosh Upadhayay; Parshant Kumar; Amit Kumar; Badal Tanwar; Nitu

Volume/Issue : Volume 11 - 2026, Issue 4 - April

Google Scholar : https://tinyurl.com/3w4c83cc

Scribd : https://tinyurl.com/ya5pxjmn

DOI : https://doi.org/10.38124/ijisrt/26apr2419

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Sweet basil, or Ocimum basilicum, is a popular therapeutic herb with potent neuroprotective properties that are enhanced by phenolics, flavonoids, and essential oils. An increasing body of research indicates that its bioactive components, including linalool, eugenol, rosmarinic acid, and ursolic acid, are essential in preventing oxidative stress, neuroinflammation, and mitochondrial dysfunction—all of which are key components of many neurodegenerative diseases. The activation of the Nrf2 antioxidant pathway, regulation of NF-κB–mediated inflammatory signaling, inhibition of acetylcholinesterase, and augmentation of neuronal survival pathways are among the molecular mechanisms by which O. basilicum exerts its protective benefits. Its relevance as a promising herbal neurotherapeutic agent is shown by preclinical studies that show its potential advantages in models of Parkinson's illness, Alzheimer's disease, epilepsy, and cognitive impairment.Clinical evidence is still scarce despite promising results, and further research is needed to determine standardized formulations, ideal dosages, and safety profiles. All things considered, O. basilicum shows itself to be a versatile herb with substantial therapeutic potential, meriting more research for its potential use in treating neurological conditions.

Keywords : Nrf2 Pathway; Neuroprotection; Antioxidant Activity; Ocimum Basilicum.

References :

1. Klimova B, Kuca K. Speech and language impairments in dementia. J Appl Biomed. 2016 Apr 1;14(2):97–103.
2. Ang. Neurodegenerative diseases: exercising towards neurogenesis and neuroregeneration. Front Aging Neurosci [Internet]. 2010 [cited 2026 Jan 19]; Available from: http://journal.frontiersin.org/article/10.3389/fnagi.2010.00025/abstract
3. Ehrhart IC, Parker PE, Weidner WJ, Dabney JM, Scott JB, Haddy FJ. Coronary vascular and myocardial responses to carotid body stimulation in the dog. Am J Physiol. 1975 Sept;229(3):754–60.
4. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016 June;8(6):595–608.
5. Duyckaerts C, Braak H, Brion JP, Buée L, Del Tredici K, Goedert M, et al. PART is part of Alzheimer disease. Acta Neuropathol (Berl). 2015 May;129(5):749–56.
6. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008 Apr 1;79(4):368–76.
7. Safarpour D, Thibault DP, DeSanto CL, Boyd CM, Dorsey ER, Racette BA, et al. Nursing home and end-of-life care in Parkinson disease. Neurology. 2015 Aug 4;85(5):413–9.
8. Mohd-Zahid MH, Jalil J, Chan KM, Azmi N. Neuroprotective Effects of Ocimum basilicum Extract against Hydrogen Peroxide-Induced Oxidative Stress in SK-N-SH Neuroblastoma Cells. Sains Malays. 2018 Sept 30;47(9):2129–39.
9. Franco FM, Knudsen M, Hassan NH, editors. Case Studies in Biocultural Diversity from Southeast Asia: Traditional Ecological Calendars, Folk Medicine and Folk Names [Internet]. Singapore: Springer Nature Singapore; 2022 [cited 2026 Jan 19]. (Asia in Transition; vol. 19). Available from: https://link.springer.com/10.1007/978-981-16-6719-0
10. Labra M, Miele M, Ledda B, Grassi F, Mazzei M, Sala F. Morphological characterization, essential oil composition and DNA genotyping of Ocimum basilicum L. cultivars. Plant Sci. 2004 Oct;167(4):725–31.
11. Telci I, Bayram E, Yılmaz G, Avcı B. Variability in essential oil composition of Turkish basils (Ocimum basilicum L.). Biochem Syst Ecol. 2006 June;34(6):489–97.
12. Kwee EM, Niemeyer ED. Variations in phenolic composition and antioxidant properties among 15 basil (Ocimum basilicum L.) cultivars. Food Chem. 2011 Oct;128(4):1044–50.
13. Kumar N, Aqil M, Najmi AK, Ismail MV, Mujeeb M. Rosmarinic acid: insights into analytical, pharmacological & pharmaceutical aspects. Braz J Pharm Sci. 2025;61:e24575.
14. Ahmed AS, Mona MM, Abdel‑Kareem MA, Elsisy RA. Potential of rosmarinic acid to ameliorate toxic effects of diethyl methoxy thio‑phosphoryl thio‑succinate on albino wistar rats’ lung, mast cell infiltration inhibitory pathway. Food Sci Nutr. 2021 July;9(7):3593–601.
15. Yahfoufi N, Alsadi N, Jambi M, Matar C. The Immunomodulatory and Anti-Inflammatory Role of Polyphenols. Nutrients. 2018 Nov 2;10(11):1618.
16. Verma RS, Padalia RC, Chauhan A, Thul ST. Exploring compositional diversity in the essential oils of 34 Ocimum taxa from Indian flora. Ind Crops Prod. 2013 Feb;45:7–19.
17. Padalia RC, Verma RS, Chauhan A. Analyses of organ specific variations in essential oils of four Ocimum species. J Essent Oil Res. 2014 Nov 2;26(6):409–19.
18. Gülçin İ, Elmastaş M, Aboul‐Enein HY. Determination of antioxidant and radical scavenging activity of Basil ( Ocimum basilicum L. Family Lamiaceae) assayed by different methodologies. Phytother Res. 2007 Apr;21(4):354–61.
19. Solak H, Gormus ZIS, Koca RO, Gunes CE, Kutlu S. Does Sertraline Affect Hypothalamic Food Intake Peptides in the Rat Experimental Model of Chronic Mild Stress-Induced Depression? Neurochem Res. 2022 May;47(5):1299–316.
20. Sadighi B, Taheri-Targhi S, Yousefi Z, Araj-Khodaei M. Medicinal Plants for Improving Cognitive Function: A Review. Int J Drug Res Clin. 2024 Feb 21;2:e22.
21. Srivastava S, Lal RK, Yadav K, Pant Y, Bawitlung L, Kumar P, et al. Chemical composition of phenylpropanoid rich chemotypes of Ocimum basilicum L. and their antimicrobial activities. Ind Crops Prod. 2022 Sept;183:114978.
22. Chaves RPF, Araújo ALD, Lopes AS, Pena RDS. Convective Drying of Purple Basil (Ocimum basilicum L.) Leaves and Stability of Chlorophyll and Phenolic Compounds during the Process. Plants. 2022 Dec 27;12(1):127.
23. Kwee EM, Niemeyer ED. Variations in phenolic composition and antioxidant properties among 15 basil (Ocimum basilicum L.) cultivars. Food Chem. 2011 Oct;128(4):1044–50.
24. Chung KKK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, et al. Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med. 2001 Oct;7(10):1144–50.
25. Jiang H, Ren Y, Zhao J, Feng J. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet. 2004 Aug 15;13(16):1745–54.
26. Sherer TB, Betarbet R, Greenamyre JT. Environment, Mitochondria, and Parkinson’s Disease. The Neuroscientist. 2002 June;8(3):192–7.
27. Houldsworth A. Role of oxidative stress in neurodegenerative disorders: a review of reactive oxygen species and prevention by antioxidants. Brain Commun. 2023 Dec 28;6(1):fcad356.
28. Rushmore TH, Morton MR, Pickett CB. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem. 1991 June;266(18):11632–9.
29. Jha SK, Jha NK, Kar R, Ambasta RK, Kumar P. p38 MAPK and PI3K/AKT Signalling Cascades inParkinson’s Disease. Int J Mol Cell Med. 2015;4(2):67–86.
30. Percie Du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research*. J Cereb Blood Flow Metab. 2020 Sept;40(9):1769–77.
31. Hossain MdJ, Samadd MdA, Urmi MstNZ, Reshmi MstFY, Hossen MdS, Rashid MA. Phytochemical Isolation and Antimicrobial, Thrombolytic, Anti-inflammatory, Analgesic, and Antidiarrheal Activities from the Shell of Commonly Available Citrus reticulata Blanco: Multifaceted Role of Polymethoxyflavones. Nutr Metab Insights. 2025 June;18:11786388251327668.
32. Sadighi B, Taheri-Targhi S, Yousefi Z, Araj-Khodaei M. Medicinal Plants for Improving Cognitive Function: A Review. Int J Drug Res Clin. 2024 Feb 21;2:e22.
33. Bora KS, Sharma A. The Genus Artemisia : A Comprehensive Review. Pharm Biol. 2011 Jan;49(1):101–9.
34. Jayasinghe C, Gotoh N, Aoki T, Wada S. Phenolics Composition and Antioxidant Activity of Sweet Basil ( Ocimum basilicum L.). J Agric Food Chem. 2003 July 1;51(15):4442–9.
35. Kim HJ, Chen F, Wang X, Rajapakse NC. Effect of Methyl Jasmonate on Secondary Metabolites of Sweet Basil ( Ocimum basilicum L.). J Agric Food Chem. 2006 Mar 1;54(6):2327–32.
36. Gülçin İ, Elmastaş M, Aboul‐Enein HY. Determination of antioxidant and radical scavenging activity of Basil ( Ocimum basilicum L. Family Lamiaceae) assayed by different methodologies. Phytother Res. 2007 Apr;21(4):354–61.
37. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988 Aug;38(8):1285–1285.
38. Barnum CJ, Tansey MG. Modeling neuroinflammatory pathogenesis of Parkinson’s disease. In: Progress in Brain Research [Internet]. Elsevier; 2010 [cited 2026 Jan 28]. p. 113–32. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0079612310840063
39. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. 2006 Feb;21(2):404–12.
40. Aloisi F. Immune function of microglia. Glia. 2001 Nov;36(2):165–79.
41. Sriram K, Miller DB, O’Callaghan JP. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor‐α. J Neurochem. 2006 Feb;96(3):706–18.
42. Banati RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson’s disease. Mov Disord. 1998 Mar;13(2):221–7.
43. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson’s disease. Brain. 2005 Nov 1;128(11):2665–74.
44. Knott C, Stern G, Wilkin GP. Inflammatory Regulators in Parkinson’s Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2. Mol Cell Neurosci. 2000 Dec;16(6):724–39.
45. Hunot S, Boissière F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, et al. Nitric oxide synthase and neuronal vulnerability in parkinson’s disease. Neuroscience. 1996 May;72(2):355–63.
46. Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord. 2005 Dec;11(8):493–8.
47. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, et al. Infiltration of CD+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2008 Dec 22;JCI36470.
48. Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in parkinson’s disease: A role in neurodegeneration? Ann Neurol [Internet]. 1998 Sept [cited 2026 Jan 28];44(S1). Available from: https://onlinelibrary.wiley.com/doi/10.1002/ana.410440717
49. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Bienfait K, et al. The Role of Inflammatory Cytokines in Cognition and Other Non-Motor Symptoms of Parkinson’s Disease. Psychosomatics. 2010 Nov 1;51(6):474–9.
50. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994 Jan;165(1–2):208–10.
51. Breder CD, Tsujimoto M, Terano Y, Scott DW, Saper CB. Distribution and characterization of tumor necrosis factor‐α‐like immunoreactivity in the murine central nervous system. J Comp Neurol. 1993 Nov 22;337(4):543–67.
52. Koziorowski D, Tomasiuk R, Szlufik S, Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson’s disease patients. Cytokine. 2012 Dec;60(3):762–6.
53. Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O. Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum. Duda J, editor. PLoS ONE. 2012 Oct 17;7(10):e47387.
54. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T. Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosci Lett. 1996 June;211(1):13–6.
55. Grigoryan GA, Gray JA, Rashid T, Chadwick A, Hodges H. Conditionally immortal neuroepithelial stem cell grafts restore spatial learning in rats with lesions at the source of cholinergic forebrain projections cholinergic forebrain projections Conditionally immortal neuroepithelial stem cell grafts restore spatial leaming in rats with lesions at the source of cholinergic forebrain projections. Restor Neurol Neurosci. 2000 Dec;17(4):1–1.
56. Mrak RE, Griffin WST. Common Inflammatory Mechanisms in Lewy Body Disease and Alzheimer Disease. J Neuropathol Exp Neurol. 2007 Aug;66(8):683–6.
57. Brodacki B, Staszewski J, Toczyłowska B, Kozłowska E, Drela N, Chalimoniuk M, et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett. 2008 Aug;441(2):158–62.
58. Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther. 2010 Dec;128(3):519–48.
59. Li D, He Q, Li R, Xu X, Chen B, Xie A. Interleukin-10 promoter polymorphisms in Chinese patients with Parkinson’s disease. Neurosci Lett. 2012 Apr;513(2):183–6.
60. Ketan C, Xiao Z, Ben-yan L. Cytokine Gene Polymorphisms and Parkinson’s Disease: A Meta-Analysis. Can J Neurol Sci J Can Sci Neurol. 2012 Jan;39(1):58–64.
61. Viana M, Barbas C, Bonet B, Bonet MV, Castro M, Fraile MV, et al. In vitro effects of a flavonoid-rich extract on LDL oxidation. Atherosclerosis. 1996 June;123(1–2):83–91.
62. Pinder RM, Sandler M. Alcohol, wine and mental health: focus on dementia and stroke. J Psychopharmacol (Oxf). 2004 Dec;18(4):449–56.
63. Moosmann B, Behl C. Antioxidants as treatment for neurodegenerative disorders. Expert Opin Investig Drugs. 2002 Oct;11(10):1407–35.
64. Berger M. Can oxidative damage be treated nutritionally? Clin Nutr. 2005 Apr;24(2):172–83.
65. Floyd RA. Antioxidants, Oxidative Stress, and Degenerative Neurological Disorders. Proc Soc Exp Biol Med. 1999 Dec;222(3):236–45.
66. Vasudevan Sajini D, Thaggikuppe Krishnamurthy P, Chakkittukandiyil A, Mudavath RN. Orientin Modulates Nrf2-ARE, PI3K/Akt, JNK-ERK1/2, and TLR4/NF-kB Pathways to Produce Neuroprotective Benefits in Parkinson’s Disease. Neurochem Res. 2024 June;49(6):1577–87.
67. Seyed MA, Ayesha S, Azmi N, Al-Rabae FM, Al-Alawy AI, Al-Zahrani OR, et al. The neuroprotective attribution of Ocimum basilicum: a review on the prevention and management of neurodegenerative disorders. Future J Pharm Sci. 2021 July 8;7(1):139.
68. Hannan MdA, Dash R, Sohag AAM, Haque MdN, Moon IS. Neuroprotection Against Oxidative Stress: Phytochemicals Targeting TrkB Signaling and the Nrf2-ARE Antioxidant System. Front Mol Neurosci. 2020 July 2;13:116.
69. Hannan MdA, Dash R, Sohag AAM, Haque MdN, Moon IS. Neuroprotection Against Oxidative Stress: Phytochemicals Targeting TrkB Signaling and the Nrf2-ARE Antioxidant System. Front Mol Neurosci. 2020 July 2;13:116.